1. Introduction {#s0005}
===============

Cervical cancer is the fourth most common neoplasm affecting women worldwide, with approximately 90% of cases occurring in developing countries ([@b0100]). Cervical cancer is a leading contributor to the increased burden of diseases in less developed regions and it is acknowledged as the second most common cancer among women in developing areas (445 000 new cases each year) and the third leading cause of cancer-related mortality in developing countries (above 230 000 deaths each year) ([@b0100], [@b0045]).

Human immunodeficiency virus (HIV)-infection is known to be a well-elucidated risk factor of cervical cancer primarily through accelerating the development of pre-cancerous lesions in the cervix ([@b0035]). HIV is also associated with higher rates of high-risk Human Papillomavirus (HR-HPV) acquisition, diminished clearance of HPV, more extensive pre-malignant lesions, and increased risk of cervical cancer when compared to HIV-negative women ([@b0055], [@b0135]). Furthermore, women with HIV have a more than two-fold risk of cervical cancer-related mortality compared to those who are HIV negative ([@b0075]).

Cervical cancer is the only gynecological cancer for which screening tools are available, providing the opportunity for early detection of its precursor lesions. Several screening tests have been implemented for cervical cancer. Based on World Health Organization (WHO) reports ([@b0260]), the Pap test (cytology) is the only screening tool that has been studied in large populations and that has been shown to has been shown to effectively lower the risk of cervical cancer and cancer-related mortality. Other alternative screening tests such as visual inspection with acetic acid (VIA) or Lugol\'s iodine (VILI) are feasible options in resource-limited settings where cytology-based screening tools are not applicable; however, there is not enough comparable evidence on their effectiveness ([@b0260]).

Despite introducing guidelines on cervical cancer screening for low- and middle-income countries (LMICs), cervical cancer screening practice is considerably low in LMICs. Studies of HIV-positive women across LMICs demonstrate relatively low utilization of cervical cancer screening services. In recent surveys carried out among HIV-positive women in Ethiopia ([@b0220]), Morocco ([@b0030]), South Africa ([@b0110]) and Laos ([@b0215]) revealed a low cervical cancer screening uptake of 24.8%, 13%, 32.5% and 5.6%, which demonstrated a large gap with developed countries where uptake of cervical cancer screening among women with HIV is 78% to 85.7% in United States ([@b0170], [@b0235]) and 53% in United Kingdom ([@b0200]). Therefore, the goal of WHO strategic planning in introducing the "comprehensive cervical cancer control" program is currently far from being achieved, since only small proportion of women have actually done cervical cancer screening in LMICs.

The lower rates of cervical cancer screening uptake have been previously attributed to numerous demographic and clinical characteristics of HIV patients (e.g., socio-demographics, clinical staging of HIV, CD4 cell count and duration on antiretroviral therapy) ([@b0015], [@b0085]). However, up to this point, not enough attention has been paid to the personal, social, and structural factors, noted by patients themselves, that may influence their decision whether to undergo screening or not.

To our knowledge, no published systematic review has addressed the question of what are the women's self-reported barriers/facilitators to cervical cancer screening in resource-limited settings in LMICs. The aim of this review was to assess the patient-reported personal, social, and structural factors influencing cervical cancer screening uptake among HIV-positive women, to notify future research, and to evaluate whether women living with HIV have different unmet needs.

2. Methods and materials {#s0010}
========================

2.1. Search strategy and study selection {#s0015}
----------------------------------------

To identify the relevant studies, two independent authors (KH and MK) electronically conducted the searches in EMBASE, MEDLINE/PUBMED and Web of Science through January 2020 based on PRISMA guidelines ([@b0155]). The subject and text words search were performed separately in all relevant databases and then combined with 'OR' and 'AND' operators. The search included the following key words: 'HIV', 'human immunodeficiency virus', 'AIDS', 'acquired immune deficiency syndrome', 'cervical cancer screening', 'pap test', 'pap smear', ''visual inspection with acetic acid', ''visual inspection with Lugol\'s iodine', 'VIA', 'VILI', 'cervical cancer', 'cervical neoplasm', 'barriers', 'facilitators', 'utilization', 'uptake', 'perception', 'attitude', 'self-reported', 'patient-reported'. The reference lists of relevant studies were also reviewed in order to detect further studies that were not captured in the primary search.

2.2. Inclusion and exclusion criteria {#s0020}
-------------------------------------

Eligibility criteria included original quantitative, qualitative, and mixed methods (both quantitative and qualitative) research studies (i.e., not review articles, meta-analyses, conference papers, commentaries, or clinical trials) that ([@b0100]) were written in English, ([@b0045]) have to be conducted in LMICs, defined as countries with a low- or middle-income status according to the World Bank's classification, ([@b0035]) must have assessed and reported patient-reported factors associated with uptake of cervical cancer screening in HIV-positive women in the quantitative literature or included factors women described as influencing their cervical cancer screening experience in the qualitative literature. Exclusion criteria were as follows: ([@b0100]) not available in full text, ([@b0045]) those that did not specifically address barriers/facilitators to uptake of cervical cancer screening, ([@b0035]) those did not clarify whether mentioned barriers/facilitators are reported by patients themselves or not (e.g., data regarding cervical cancer screening may extracted from medical charts or data registrations). It is important to note that during the reporting the results of included studies consisted of both HIV-positive and HIV-negative women, only data on HIV-positive subgroup was included and reported in the current review.

2.3. Data extraction and quality assessment {#s0025}
-------------------------------------------

Data extraction and study quality assessment were performed independently by two researchers (HV and MK). In the case of disagreement among the 2 reviewers, it would be resolved by discussion with third author (NA). Regarding the study quality assessment, we used the Mixed Methods Appraisal Tool (MMAT), a tool designed for the quality appraisal of qualitative, quantitative and mixed-methods studies ([@b0175]). No study was excluded due to a low-quality assessment score.

We used summary tables to extract study characteristics of selected articles (i.e., authors, year and setting of the study, sample size, study design, age and screening status of participants, and main outcomes) along with quality assessment results. After reviewing and identifying several patient-reported factors associated with uptake of cervical cancer screening across included studies, these factors were grouped into three categories including personal, social, and structural barriers/facilitators based on "women's autonomy in healthcare decision-making" ([@b0205]), in order to organize a comprehensive overview of cervical cancer screening challenges among HIV-positive women living in LMICs. Briefly, personal factors include, but not limited to, knowledge and attitude, perceived susceptibility, embarrassment, fear of the cervical cancer screening procedure and test results, and experiencing cervical cancer-related symptoms. Social factors include the effectiveness of the patient--HCP relationship, stigma, information sources and social support from friends and family members. Structural factors include the screening costs, healthcare facility accessibility, time issues and resources/infrastructures.

3. Results {#s0030}
==========

3.1. Search results and study characteristics {#s0035}
---------------------------------------------

A total of 7896 articles were retrieved from the electronic databases search. After screening records, 32 articles were found to be eligible for inclusion in this review. The details of step by step study identification and selection are shown in [Fig. 1](#f0005){ref-type="fig"}. Among 32 included articles in the review, twenty-six studies were quantitative and mixed methods (21 quantitative and 5 mixed methods) and 6 studies were qualitative ([Table 1a](#t0005){ref-type="table"}, [Table 1b](#t0010){ref-type="table"}, [Table 1c](#t0015){ref-type="table"}, [Table 1d](#t0020){ref-type="table"} and [2](#t0025){ref-type="table"}). The design of all of the quantitative studies were cross-sectional. The majority of the qualitative studies were designed as in-depth interviews (n = 4), one of them as focus group discussions and the last one includes both in-depth interviews and focus group discussions. The proportion of HIV-positive women participating in cervical cancer screening, at least once in lifetime, ranged from 0.7% to 88%. Twelve studies focused on Pap test, three on visual inspection methods (VIA/VILI), three on visual inspection methods and Pap test, and 14 looked generally at cervical cancer screening without specifying a particular screening method. Forty-four percent of the studies were published in years 2018 or later, and twenty-nine studies were carried out in African, two in Asian and one in Southern American LMICs.Fig. 1Literature search and review flowchart for selection of studies.Table 1aQuantitative and mixed-method studies conducted in Western Africa.First author, yearCountryStudy designStudy settingPopulationAgeScreening statusType of screeningPatient-reported factors influencing women's cervical cancer screening experience. The (+/−) signs indicate women's perception of how these factors influenced their screening experience.MMAT score[@b0070])NigeriaCross-sectional studyVoluntary Counseling and Testing (VCT) clinic of the University of Nigeria Teaching Hospital in Enugu, Nigeria150 HIV-positive women and 150 HIV-negative women21--54 years, mean age 34.9 year0.7% screened at least oncePap test***Personal*** low awareness of cervical cancer (78%) (−), low perception about being at risk of cervical cancer among HIV-positive women (12.1%) (−), low awareness of pap-smear among HIV-positive women (4%) (−)50%[@b0005])NigeriaDescriptive cross-sectional studyART clinic at the Nnamdi Azikiwe University Teaching Hospital, tertiary health care in Nnewi, south-eastern Nigeria447 HIV-positive womenNR10% screened at least oncePap test***Personal*** not heard of cervical cancer screening (61.8%) (−), not heard of HPV (86.4%) (−), not heard of HPV vaccine (88.8%) (−), fear of screening procedure (1.8%) (−), screening not necessary (21%) (−), negative attitude toward screening (56.5%) (−), had a previous Pap test (+), had a previous gynecological visit (+), awareness on cervical cancer (+)\
***Social*** information sources \[media, (23%) and HCP (19.9%)\] (+), bad attitude of nurses (0.7%) (−), discouraged by partner (1.3%) (−)\
***Structural*** too expensive (0.9%) (−)75%[@b0095])NigeriaCross-sectional studyHIV treatment center, Nigerian Institute of Medical Research\
(NIMR), Lagos1517 HIV-positive women18--57 years, mean age 31 year9.4% screened at least onceNR***Personal*** awareness of cervical cancer (OR: 1.53) (+), fear of test outcome (4.2%) (−), pregnant/recently delivered (10.7%) (−)\
***Social*** need to obtain partner's approval (12.4%) (−), religious denial (14.0%) (−)\
***Structural*** expensive cervical cancer screening (35.2%) (−), long waiting time (12.7%) (−)75%[@b0180])NigeriaDescriptive cross-sectional studyART clinic of the Lagos State University Teaching Hospital, Ikeja, Lagos State, Nigeria300 HIV-positive women17--60 years, mean age 34 year31.3% screened at least oncePap test***Personal*** never heard of cervical cancer (74.7%) (−), never heard of the Pap test (84%) (−), fear of the result (9.1), does not feel susceptible to cervical cancer (12.1) (−)\
***Social*** information sources \[media electronic and printed (33.3%), friends and relatives (20.8%), medical personnel (16.7%)\] (+)\
***Structural*** expensive cervical cancer screening (9.1%) (−)50%[@b0230])Ivory Coast (Côte d'Ivoire)Cross-sectional studyOutpatient setting in the four highest volume urban HIV clinics of government's or non-governmental organisation's sector in Côte d'Ivoire1991 HIV-positive womenInter Quartile Range of 37--47 years, median age 4259.7% screened at least oncePap test and VIA***Personal*** being informed on cervical cancer at the HIV clinic (OR: 1.5) (+), clarity of information on cervical cancer (OR: 1.7) (+), identifying HIV as a risk factor for cervical cancer (OR: 1.4) (+), being proposed cervical cancer screening in the HIV clinic (OR: 10.1) (+), receiving advise for repeated cervical cancer screening over time (65.5%) (+), accept screening as part of a research project (15.8%) (+), lack of information about cervical cancer (54%) (−), fear of the result of screening (22%) (−), negligence (15%) (−)\
***Structural*** fear of cervical cancer screening cost (10%) (−)75%[@b0080])GhanaDescriptive cross-sectional studyHIV health facilities in the Central Region of Ghana660 HIV-positive women20--65 yearsNRNR***Personal*** perceived Benefits of cervical cancer screening (OR: 1.68) (+), perceived Seriousness of cervical cancer (OR: 2.02) (+), cues about cervical cancer screening (OR :3.48) (+)100%[@b0225])GhanaMixed methodsCape Coast Teaching\
Hospital in Cape Coast, Ghana55 HIV-positive women and 76 HIV-negative womenMean age 42.9 yearNRNR***Personal*** embarrassing (35.6%) (−), not painful examination based on previous experience with cervical cancer screening (85.0%) (+), worried about the results of screening (43.3%) (−)\
***Social*** given enough information about HPV, cervical cancer, and screening before the screening (88.3%) (+)\
***Structural*** would have cervical cancer screening again if it was free (91.4%) (+)50%[^1]Table 1bQuantitative and mixed-method studies conducted in Southern Africa.First author, yearCountryStudy designStudy settingPopulationAgeScreening statusType of screeningPatient-reported factors influencing women's cervical cancer screening experience. The (+/−) signs indicate women's perception of how these factors influenced their screening experience.MMAT score[@b0110])South AfricaCross-sectional studySecondary referral obstetrics and gynecology hospital, Lower Umfolozi District War Memorial Hospital, in rural KwaZulu-Natal79 HIV-positive women and 155 HIV-negative women18--70 years, mean age 29 year32.5% screened at least oncePap test***Personal*** never heard of a Pap test (27.1%) (−), too scared/too painful (19.4%) (−), never offered cervical cancer screening (12.9%) (−), feel well so do not need cervical cancer screening (being asymptomatic) (5.8%) (−), do not want to know the result (1.9%) (−), not old enough for cervical cancer screening (1.9%) (−), being symptomatic 57.9% (+)\
***Social*** Offered to them by HCP (42.1%) (+)\
***Structural*** did not know where or when to have cervical cancer screening (6.5%) (−), not enough time to get screened (5.8%) (−)75%[@b0125])South AfricaMixed-methods\*Rural HIV clinic in Limpopo Province, South Africa403 HIV-positive women for quantitative and 12 HIV-positive women for qualitative studyNRNRVIA and Pap test***Personal*** discomfort with the position required for undergoing cervical cancer screening (−), knowledgeable about the purpose of VIA and pap test (+), left behind in follow-up care (−)\
***Structural*** understaffing (−), long waiting time (−)25%[@b0130])South AfricaDescriptive cross-sectional studyAdult HIV unit at a publichospital in Johannesburg, South Africa315 HIV-positive women27--54 years, mean age 38.9 yearNRPap test***Personal*** fear of the procedure (39.3%) (−), not ill so screening not necessary (7.4%) (−)\
***Social*** information sources \[nurse or doctor (61%), community health worker (50.8%), classmates (9.8%) and relative and parents (7.6%)\] (+), bad attitude of nurses and doctors (8.1%) (−)50%[@b0245])South AfricaCross-sectional studyART clinic at GF Jooste Hospital, Cape Town, South Africa100 HIV-positive women21--64 years, mean age 32.8 year59% screened at least oncePap test***Personal*** had never been asked to get cervical cancer screening (35.7%) (−), had never heard of the Pap test (28.6%) (−), fear and misunderstanding of cervical cancer screening (−)\
***Structural*** unable to attend cervical cancer screening due to inappropriate time and place (19.6%) (−)50%[@b0150])BotswanaCross-sectional studyTwo public health clinics in Gaborone, Botswana163 HIV-positive women and 117 HIV-negative women20--84 years72% screened at least oncePap test***Personal*** ever heard of cervical cancer (OR: 3.28) (+), to know if cervix is healthy (56%) (+), to get early treatment (34%) (+), improve overall health (33%) (+), being symptomatic (10%) (+), protecting future fertility/pregnancy (8%) (+)50%[^2][^3]Table 1cQuantitative and mixed-method studies conducted in Eastern Africa.First author, yearCountryStudy designStudy settingPopulationAgeScreening statusType of screeningPatient-reported factors influencing women's cervical cancer screening experience. The (+/−) signs indicate women's perception of how these factors influenced their screening experience.MMAT score[@b0010])EthiopiaCross-sectional studyThree public health facilities providing both cervical cancer screening and assisted reproductive technology services in Hawassa, Ethiopia342 HIV-positive womenMean age 33.4 year40.1% screened within previous five yearsNR***Personal*** no need for cervical cancer screening due to no symptoms (34.1%) (−), fear of test results (16.1%) (−), fear of painful examination (11.2%) (−), positive attitude towards cervical cancer and screening (+), knowledge about cervical cancer risk factors (+)\
***Social*** partner or husband support (+)\
***Structural*** do not know the place for cervical cancer screening (6.3%) (−), expensive (2%) (−)75%[@b0025])EthiopiaMixed methodsPublic health institutions of HIV care in Addis Ababa, Ethiopia322 HIV-positive women for quantitative and 14 HIV-positive women for qualitative studyMean age 35.7 years11.5% screened at least onceNR***Personal*** being pregnant or in peripartum period (13.3%) (−), fear of test result (30.8%) (−), knowledge about risk factors and prevention of cervical cancer (+)\
***Social*** information sources \[media, (58.2%) and HCP (53.6%)\] (+), partner acceptance (10%) (+), religious denial (10%) (−)\
***Structural*** expensive cervical cancer screening (30%) (−), lack of female screeners (13.3%) (−), time consuming (35.8%) (−)75%[@b0090])EthiopiaCross-sectional studyART clinic at University of Gondar\
Referral and Teaching Hospital, Ethiopia302 HIV-positive womenMean age 33.7 year23.5% screened at least onceNR**Personal** comprehensive knowledge about cervical cancer screening (OR: 3.02) (+), perceived susceptibility of cervical cancer (OR: 2.85) (+), absence of symptoms (88.7%) (−), embarrassment (68.8%) (−), fear of test result (71%) (−), not prescribed by the doctor (32.9%) (−)\
**Structural** expensive cervical cancer screening (27.7%) (−), Screening center too far (37.7%) (−), time consuming (19%) (−)75%[@b0210])EthiopiaMixed methodsPublic (community) health centers in Addis Ababa, the capital city of Ethiopia581 HIV-positive women21--64 years, mean age 34.9 year10.8% screened at least onceNR***Personal*** feeling healthy (36.5%) (−), never think of cervical cancer (23.9%) (−), lack of awareness about cervical cancer screening (9.6%) (−), embarrassing (5.5%) (−), fear of positive results (5.3%) (−), painful screening procedure (1.2%) (−)\
***Social*** partner negative attitude toward cervical cancer screening (1.4%) (−), religion factors (0.9%) (−), HCP negative attitude (0.7%) (−), no appropriate care at health care facilities (6.2%) (−), HCP do not have good knowledge (1.4%) (−)\
***Structural*** did not know where to get cervical cancer screening (20.1%) (−), expensive cervical cancer screening (5.7%) (−), no health facility in the catchment area (4.3%) (−)75%[@b0220])EthiopiaCross-sectional studyHospital based setting In Bishoftu town, East Shoa, Ethiopia475 HIV-positive women18--67 years, mean age 36.2 year24.8% screened at least onceVIA***Personal*** fear of positive result (28%) (−), being symptomatic (33.1%) (+), perceived self-efficacy (OR: 1.24) (+), perceived threat of cervical cancer (OR: 1.08) (+), perceived net benefit (OR: 1.18) (+)\
***Social*** information sources \[HCP (81.2%), media printed and non-printed (15.9%), close relatives (2.9%)\] (+), partner negative attitude toward cervical cancer screening (15%) (−), HCP advice on cervical cancer screening (64.4%) (+), relatives (family/friends) advice (2.5%) (+)100%[@b0160])KenyaMixed methodsKenyatta National Hospital, Nairobi, Kenya387 HIV-positive women for quantitative study and 4 focus group discussions (each group = 6--8 HIV-positive women)Inter Quartile Range of 36--44 years, median age 4046.3% screened at least onceNR***Personal*** quality of information on cervical cancer screening services above average (OR 5.4--8.9) (+), had previous experience with cervical cancer screening before attending clinic (OR: 2.9) (+), fear of pain or excessive bleeding (−), young age and male gender of the HCP conducting the cervical cancer screening (−)\
***Social*** cervical cancer screening recommended by HCP (OR: 10) (+)\
***Structural*** long waiting time (−)50%[@b0185])KenyaDescriptive cross-sectional studyVoluntary counseling and testing centers in Nairobi, Kenya268 HIV-positive women and 141 HIV-negative womenInter Quartile Range of 24--34 years, median age 2814% screened at least oncePap test***Personal*** cervical cancer screening being part of routine care (42%) (+), cervical cancer screening being part of research study (19%) (+), being symptomatic (bleeding and abdominal pain) (6%) (+), did not know what cervical cancer screening is/why needed (78%) (−), knowledge of Pap test (OR: 1.8) (+), knowledge of HPV (OR: 1.7) (+), previous experience with Pap test (OR: 1.9) (+)\
***Structural*** expensive cervical cancer screening (2%) (−), did not know where to get screened (4%) (−)75%[@b0190])KenyaCross-sectional studyIntegrated HIV clinic in the Nyanza Province of Kenya106 HIV-positive women23--64 years, mean age 34.9 year15% screened at least onceNR***Personal*** screening by a male provider (8%) (−)\
***Structural*** not willing to get screened if they had to pay (48%) (−)75%[@b0050])ZimbabweDescriptive cross-sectional studyBindura Provincial Hospital, Zimbabwe70 HIV-positive women19--49 years, mean age 35.7 yearNRNR***Personal*** lack of Knowledge about risk factors of cervical cancer (90%) (−), low of perception about being at risk of cervical cancer among HIV-positive women (74.3%) (−), awareness of cervical cancer scored below the average (97.2%) (−)\
***Social*** information sources \[media, friends and relatives (40.5%), nurses (35.1%), general practitioner (10.8%), counselor (8.1%) and gynecologist (5.4%)\] (+), lack of health education by HCP at clinic (97.1%) (−)25%[@b0120])TanzaniaCross-sectional studyHIV clinics in Dar es Salaam, Tanzania399 HIV-positive women≥19 years9% screened at least onceNR***Personal*** had not been informed about care and treatment of cervical cancer at clinic (65.7%) (−)\
***Social*** information sources \[media (47.4%), hospital staff (39.3%), friends and families (4.8%)\] (+),\
***Structural*** free cervical cancer screening (83.3%) (+), free cervical cancer treatment (77.8%) (+), time to travel to clinic \> 120 min (18.8%) (−)100%[@b0250])UgandaNationwide cross-sectional study245 public and private HIV clinics across the five geographical regions (Central, Northern, Eastern, Western, and Kampala) in Uganda5198 HIV-positive women15--49 years30.3% screened at least onceNR***Personal*** lack of information on cervical cancer screening (29.6%) (−), had been told that procedure is painful (10.5%) (−), fear of receiving a cancer diagnosis (40.6%) (−), embarrassing (22.3%) (−), knowledgeable of cervical cancer screening (PR: 2.19) (+), low risk perception (PR: 1.52) (+)\
***Structural*** lack of screening facilities 14% (−), know any place where cervical cancer screening is offered (PR: 6.47) (+), did not have time (25.5%) (−)100%[^4]Table 1dQuantitative and mixed-method studies conducted in other countries.First author, yearCountryStudy designStudy settingPopulationAgeScreening statusType of screeningPatient-reported factors influencing women's cervical cancer screening experience. The (+/−) signs indicate women's perception of how these factors influenced their screening experience.MMAT score[@b0030])MoroccoCross-sectional studyHIV treatment center at the Hospital of Moulay Hassan Ben Elmehdi in Laâyoune city, Morocco115 HIV-positive womenMean age 34.9 years13% screened at least oncePap test***Personal*** lack of knowledge of cervical cancer risk factors (79.1%) (−), absence of symptoms (47%) (−), never heard of a Pap test (22%) (−), fear of abnormal results (13%) (−), fear of painful sampling (7%), shame or embarrassment (7%) (−), absence of sexual activity (3%) (−)\
***Social*** information sources \[media, (17.4%), friends/family (2.6%), HCP (0.9%)\] (+)50%[@b0060])PeruCross-sectional studyVía Libre non-governmental organization (NGO) HIV center in Lima, Peru71 HIV-positive women19--60 years, mean age 40.4 year12.7% never had a Pap test, 77.5% had over 1 year ago, 9.8% within 1 yearPap test***Personal*** good knowledge on cervical cancer screening interval and frequency (75%) (+), low perception about being at risk of cervical cancer among HIV-positive women (37.5%) (−), good knowledge on certain types of the HPV that can cause cervical cancer (75%) (+)50%[@b0215])LaosCross-sectional case--control studyHIV treatment centers of three provinces of Lao PDR, Vientiane, Luang Prabang and Savannakhet320 HIV-positive women (cases) and 320 HIV-negative women (controls)25--63 years, mean age 36.2 year5.6% screened at least oncePap test***Personal*** no symptoms (46%) (−), never heard of cervical cancer screening (21.2%) (−), screening not necessary (10.9%) (−), not prescribed by the doctor (7.3%) (−)\
***Structural*** not enough cervical cancer screening services available (5.6%) (−),100%[^5]Table 2Qualitative studies included.First author, yearCountryStudy designStudysettingPopulationAgeScreening statusType of screeningPatient-reported factors influencing women's cervical cancer screening experience. The (+/−) signs indicate women's perception of how these factors influenced their screening experience.MMAT score[@b0020])TanzaniaFocus group discussionsTwelve Management and Development for Health (MDH) public HIV centers in Dar es Salaam, Tanzania19 HIV-positive women24--57 yearsNRNR***Personal*** lack of knowledge on cervical cancer screening (−), fear of examination (−)\
***Social*** information sources (+), participating in patient navigation programs (+), cancer-related stigma (−)75%[@b0040])UgandaIn-depth interviewHIV specialist care organization of Mildmay Uganda18 HIV-positive women≥25 years1/3 not screened, 1/3 screened once, 1/3 screened on a regular basisVILI, VIA***Personal*** risk perception associated with HIV (+), misconceptions about the cervical cancer screening process (−), fear of painful examination and other screening-related side effects (−), current poor health status of the women (excessive weight loss, DM, HTN) (−), competing health priorities (tuberculosis and antiretroviral therapy) (−), embarrassment (−), poor hygiene (−)\
***Social*** lack of health education (−), lack of a proper follow-up reminder (−)\
***Structural*** long waiting time (−)100%[@b0115])IndiaSemi-structured in-depth interviewsNew Civil Hospital ART Centrein Surat, India25 HIV-positive women30--54 years, mean age 37.2 year88% screened at least oncePap test***Personal*** concerns about HIV status disclosure (−)\
***Social*** HIV-related stigma at healthcare facilities (−), support from friends and/or family members (+), confidential communication with physician (+)75%[@b0140])BotswanaSemi-structured interviewsOodi rural clinic in the Kgatleng district of Botswana14 HIV-positive women29--49 years, mean age 37.4 year71.4% screened at least oncePap test and VIA***Personal*** delays in getting the test results (−), being employed (−), getting an appointment for the cervical cancer screening (−), lack of instruction by HCP (−), lack of knowledge Pap test and risk factors of cervical cancer (−), fear of painful examination (−), embarrassment (−), fear from positive results (−), lack of knowledge about treatment modalities for precursor lesions of cervical cancer (−), alcohol misuse (−)\
***Structural*** long distance from the clinic (−), unpredictability of public transport for the clinic (−), equipment shortages at the clinic (−), long waiting time (−)50%[@b0165])ZambiaIn-depth interviewsUrban and rural health care facilities in Lusaka and Chongwe districts, Zambia19 HIV-positive women, 19 HIV-negative women and 2 women with unknown HIV status25--49 years52.5% screened at least onceNR***Personal*** importance of early detection of precancerous lesions (+), misconceptions about risk factors of cervical cancer (−), fear of painful examination (−), lack of time and reluctance (−)50%[@b0255])ZambiaFocus group discussions and in-depth interviewsZambian Ministry of Health primary health center in Kanyama20 HIV positive women and 40 HIV-negative women18--49 yearsNRVIA***Personal*** protecting future pregnancy (+), screening test was performed quickly (+), undressing for the exam (−), fear of painful examination (−), potential of contracting diseases from examination (−)\
***Social*** supportive attitudes of staff (+), confidential communication with staff (+), encouragement from close friends and husbands (+), cancer-related stigma (−),\
***Structural*** free healthcare services (+), understaffing (−)75%[^6]

3.2. Patient-reported barriers and facilitators {#s0040}
-----------------------------------------------

### 3.2.1. Personal factors {#s0045}

*Knowledge and attitude toward cervical cancer and screening*

HIV-positive women with low knowledge of cervical cancer ([@b0030], [@b0050], [@b0070], [@b0120], [@b0140], [@b0180], [@b0230]) and cervical cancer screening ([@b0070], [@b0140], [@b0180], [@b0030], [@b0110], [@b0215], [@b0005], [@b0020], [@b0185], [@b0210], [@b0245], [@b0250]) were less likely to undergo screening. Conversely, adequate knowledge of cervical cancer ([@b0230], [@b0005], [@b0010], [@b0025], [@b0090], [@b0095], [@b0150]) and cervical cancer screening ([@b0185], [@b0250], [@b0090], [@b0060], [@b0080], [@b0125], [@b0160]) was associated with higher rates of cervical cancer screening uptake by patients. Two studies evaluated HIV-positive women's attitudes toward cervical cancer screening and reported that positive attitude ([@b0010]), despite negative one ([@b0005]), is associated with increased rate of cervical cancer screening uptake.

*Perceived susceptibility of cervical cancer*

The majority of studies showed a low perceived susceptibility of cervical cancer among HIV-positive women ([@b0050], [@b0070], [@b0180], [@b0250], [@b0060]). This low perceived susceptibility was associated with a decreased uptake of cervical cancer screening in most of studies, except for one study that showed low perceived susceptibility was significantly associated with higher uptake of cervical cancer screening ([@b0250]). On the other hand, a number of previous studies found that greater perceived susceptibility of cervical cancer was associated with increased uptake of cervical cancer screening by study subjects ([@b0220], [@b0090], [@b0040]).

*Embarrassment*

Among included surveys, embarrassment/shame of showing private parts of body and pelvic examination were among main reasons for not seeking cervical cancer screening facilities, and this barrier's prevalence ranged from 5.5% to 68.8% among respondents ([@b0030], [@b0140], [@b0210], [@b0250], [@b0090], [@b0040], [@b0225], [@b0255]). Additionally, the male gender of the healthcare provider (HCP) performing the cervical cancer screening appeared to be a barrier in uptake of cervical cancer screening by HIV-positive women ([@b0160], [@b0190]).

*Fear of the screening procedure and test results*

Most of studies reported fear of the screening procedure as a potential barrier to get screened among HIV-positive women ([@b0030], [@b0110], [@b0140], [@b0005], [@b0020], [@b0255], [@b0130], [@b0165], [@b0210], [@b0245], [@b0250], [@b0010], [@b0125], [@b0160], [@b0040]). In most of the cases, this was related to the fear of painful pelvic examination, bleeding or contracting diseases through cervical cancer screening. Interestingly, one study reported that HIV-positive women with previous experience of cervical cancer screening, who reported painless and comfortable cervical cancer screening experience, were more likely to accept and undergo following cervical cancer screening ([@b0225]). Furthermore, fear of being diagnosed with cancer and fatalistic beliefs about cervical cancer make HIV-positive women less likely to go for a cervical cancer screening ([@b0210], [@b0225], [@b0220], [@b0030], [@b0110], [@b0140], [@b0180], [@b0230], [@b0250], [@b0010], [@b0025], [@b0090], [@b0095]).

*Experiencing cervical cancer-related symptoms*

Being asymptomatic was identified as a barrier to cervical cancer screening in a large number of studies, as lack of symptoms was incorrectly considered a sign of well-being ([@b0110], [@b0215], [@b0210], [@b0010], [@b0090], [@b0130]). However, experiencing signs and symptoms of cervical cancer (mainly abdominal pain and bleeding) was a trigger for uptake of cervical cancer screening among HIV-positive women noted by three studies ([@b0220], [@b0185], [@b0150]).

*Other self-reported personal factors influencing cervical cancer screening uptake*

Previous experience of cervical cancer screening was reported as a facilitator for undergoing subsequent cervical cancer screenings ([@b0005], [@b0185], [@b0160]). Being pregnant or in peripartum period was a barrier to cervical cancer screening ([@b0025], [@b0095]); however, desire for pregnancy in future and preserving fertility was a facilitator for cervical cancer screening uptake ([@b0150], [@b0255]). Current medical illnesses (such as advanced stage of AIDS, diabetes or hypertension, etc.) and health priorities other than cervical cancer were considered as screening barriers by HIV-positive women ([@b0040]).

### 3.2.2. Social factors {#s0050}

*Patient--HCP relationship*

The effectiveness of the patient--HCP relationship was acknowledged as having a significant effect on cervical cancer screening uptake. Accordingly, women who were well informed by their HCPs regarding the cervical cancer and screening methods were more likely to get screened ([@b0220], [@b0110], [@b0160], [@b0225], [@b0255], [@b0115]). In contrast, poor patient-HCP relationship and negative attitude of HCPs toward HIV-positive women were considered a barrier toward cervical cancer screening uptake ([@b0005], [@b0210], [@b0130]).

*Stigma*

Fear of cancer-related stigma lead to patients avoiding cervical cancer screening ([@b0020], [@b0255]). Also, HIV related stigma and concerns regarding HIV status disclosure were mentioned as barriers to cervical cancer screening ([@b0115]).

*Information sources*

There seems to be a variety of information sources for cervical cancer and its screening such as media, HCPs, family and friends, and etc. The majority of studies noted media as the main information source ([@b0030], [@b0050], [@b0120], [@b0180], [@b0005], [@b0025]), while a lower number of studies noted HCPs as the main sources of information on cervical cancer ([@b0220], [@b0130]).

*Social support from friends and family members*

Encouragement from family members to attend screening, particularly spousal encouragement, was an important motivator for women ([@b0220], [@b0010], [@b0025], [@b0255], [@b0115]). Women who reported negative attitude of their husband/partner toward cervical cancer screening were less likely to undergo screening ([@b0005], [@b0210], [@b0095]).

*Other self-reported social factors influencing cervical cancer screening uptake*

Religious beliefs and values seem to influence the uptake of cervical cancer screening across the ethnic and racial diversity of HIV-positive women ([@b0025], [@b0095]). In the latter studies, some participants share concerns for maintaining modesty during cervical cancer screening.

### 3.2.3. Structural factors {#s0055}

*Screening costs*

HIV-positive women from ten studies specified that financial issues and screening costs were a barrier to cervical cancer screening ([@b0185], [@b0210], [@b0190], [@b0180], [@b0230], [@b0005], [@b0010], [@b0025], [@b0090], [@b0095]), while a free screening opportunity was associated with an increased interest of women to get screened for cervical cancer ([@b0255]). In another report by Stuart et al. ([@b0225]), 91.4% of HIV-positive women noted that if screening was free, they would do it again. Free cervical cancer screening and cancer-treatment was noted as a facilitator of screening uptake in one study ([@b0120]).

*Healthcare facility accessibility and time issues*

Not knowing a place where cervical cancer screening is done or being out of catchment of a healthcare facility providing screening services were among barriers to uptake of cervical cancer screening ([@b0110], [@b0215], [@b0140], [@b0010], [@b0090], [@b0185], [@b0210], [@b0245]). Time limitations and long waiting time at clinics were noted as barriers by a majority of women ([@b0110], [@b0120], [@b0140], [@b0245], [@b0250], [@b0165], [@b0025], [@b0090], [@b0095], [@b0125], [@b0160], [@b0040]).

*Resources/infrastructures*

Lack of facilities needed for cervical cancer screening ([@b0140], [@b0250]) and understaffing ([@b0025], [@b0125], [@b0255]) were other two barriers to cervical cancer screening.

4. Discussion {#s0060}
=============

To the best of our knowledge, this is the first review to summarize only the patient-reported factors influencing cervical cancer screening uptake by HIV-positive women in LMICs. The results of included studies suggest that the rates of uptake of cervical cancer screening among HIV-positive patients from LMICs were below the national and global recommendations. HIV-positive women most commonly highlighted personal (knowledge and attitude, perceived susceptibility, embarrassment and fear of the procedure and test results), social (patient--HCP relationship, stigma, information sources, support from family/friends and religious factors) and structural (costs, accessibility and time issues, resources and infrastructure) variables as key factors playing a prominent role in their screening decision making.

The WHO recommends that \> 80% of women ages 35--59 years should have been screened at least once during their lifetime ([@b0260]). Furthermore, some strategic actions have been taken in order to achieve this goal, such as integration of cervical cancer prevention programs with HIV/AIDS care ([@b0195]). However, the low rates of cervical cancer screening uptake in LMICs indicates the failure in the implementation of screening programs in such a substantial scale in these countries ([@b0195]).

Our findings are to some extent consistent with the results of a previous systematic review, which analyzed the barriers associated with cervical cancer screening uptake in LMICs. Lack of knowledge and awareness, psychological (embarrassment or shyness), structural, sociocultural and religious barriers were among the most commonly reported factors influencing women's decision to undergo cervical cancer screening ([@b0065]). In another review by McFarland et al. ([@b0145]) evaluating barriers to Pap test screening among women living in sub‐Saharan Africa, reported individuals' barriers were lack of knowledge and awareness about Pap test, fear of cancer, belief of not being at risk for cervical cancer, and that a Pap test is not important unless being symptomatic and cultural or religious factors. Provider-level barriers were failure to inform or encourage women to get cervical cancer screening. Major system-related barriers were low availability and accessibility of the cervical cancer screening. However, in contrast to our review, previous reviews did not exclusively focus on HIV-positive women to identify whether they have different barriers or information needs regarding cervical cancer screening uptake.

There seems to be considerable overlap between the HIV-positive and HIV-negative population in terms of barriers influencing their uptake of cervical cancer screening. For instance, in a non-HIV cohort of women, similar to our findings, lack of knowledge about cervical cancer risk factors, treatment, and prevention strategies, painful screening experiences, embarrassment and other personal and institutional barriers were noted as common challenges affecting cervical cancer screening ([@b0085]).

Despite previous well-established challenges in cervical cancer screening among general population, HIV-related stigma is a unique barrier exclusively affecting HIV-positive women ([@b0115]). A high proportion of HIV-positive women have noted facing HIV-stigma both in healthcare settings and community contexts ([@b0115], [@b0240]). These concerns include being treated poorly by HCPs and being rejected or loss the support of families or friends after HIV-status disclosure. Unfortunately, the vicious cycle of HIV-stigma and lack of HIV status disclosure is a barrier negatively affecting cervical cancer screening uptake, leading to smaller number of HIV-positive women obtaining recommended cervical cancer care (both prevention and treatment) ([@b0115]). Previous research noted that discrimination and stigma against HIV-positive women are more prevalent in LMICs ([@b0105]); therefore, this review's findings highlights that prompt actions must be taken in order to decrease HIV-related stigma and discrimination and increase the delivery of recommended health care to HIV-positive women.

*Strengths and limitations*

This review was the first of its kind to assess patient-reported barriers/facilitators to uptake of cervical cancer screening among HIV-positive women in LMICs. This review highlights the perspectives of HIV-positive women and thus could be used as a valuable resource for further research and health promotion actions. This collective evidence has fundamental implications for education, policy, and further research. Our review was limited by the variable quality of included studies.

5. Conclusions {#s0065}
==============

This review has raised numerous barriers and facilitators at personal, social and structural levels hindering the use of cervical cancer screening services among HIV-positive women in LMICs. This provides concrete evidence for the use of multilevel strategies, by targeting health professionals, policy-makers, patients and their families, in order to promote the uptake of cervical cancer screening services by HIV-positive women in countries with limited resources.
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[^1]: *ART* anti-retroviral therapy, *HCP* healthcare provider, *HIV* human immunodeficiency virus, *MMAT* mixed methods appraisal tool, *NR* not reported, *OR* odds ratio, *VIA* visual inspection with acetic acid.

[^2]: *ART* anti-retroviral therapy, *HCP* healthcare provider, *HIV* human immunodeficiency virus, *MMAT* mixed methods appraisal tool, *NR* not reported, *OR* odds ratio, *VIA* visual inspection with acetic acid

[^3]: \*Quantitative data of this mix-methods study is not presented since it was not patient-reported factors and it only reported patients' medical records data.

[^4]: *ART* anti-retroviral therapy, *HCP* healthcare provider, *HIV* human immunodeficiency virus, *MMAT* mixed methods appraisal tool, *NR* not reported, *PR* prevalence ratio, *OR* odds ratio, *VIA* visual inspection with acetic acid.

[^5]: *HCP* healthcare provider, *HIV* human immunodeficiency virus, *MMAT* mixed methods appraisal tool.

[^6]: *ART* anti-retroviral therapy, *HCP* healthcare provider, *HIV* human immunodeficiency virus, *MMAT* mixed methods appraisal tool, *NR* not reported, *VIA* visual inspection with acetic acid, *VILI* visual inspection with Lugol's iodine.
